Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Colleen B Jonsson · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2023 · $1,216,129 — PROJECT ABSTRACT The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development of countermeasures for prophylactic or therapeutic treatment of human biosafety le…
ELIZABETH ANN FITZPATRICK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2023 · $744,995 — The University of Tennessee Health Science Center (UTHSC) Regional Biocontainment Laboratory (RBL) provides a vast array of services that support the discovery and development of countermeasures for biodefense and emerging infectious agents with unmet medical needs. Central to this mission is the su…
Thomas William Geisbert · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $2,317,735 — PROJECT 3 – ABSTRACT The goal of this project is to discover novel henipavirus inhibitors. Henipavirus is a deadly airborne respiratory pathogen that are under-researched and poorly understood. Antiviral therapy is urgently needed for henipaviruses for pandemic preparedness. We will achieve the goal…
BLANCA I RESTREPO · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2023 · $956,440 — ABSTRACT Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), is a leading infectious disease and cause of death worldwide. The growing burden of drug-resistant (DR)-TB is complicating TB treatment. Early diagnosis of TB with drug susceptibility testing (DST) is critical for successful tr…
Patricia Veronica Aguilar · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $297,402 — Abstract Non-malarial acute undifferentiated febrile illnesses (AUFIs) are significant causes of morbidity and mortality in Latin America, and the incidence of dengue-like illness has increased dramatically in recent years. As in most low-and middle-income countries, only a handful of “dengue” cases…
Yoshihiro Izumiya · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $529,822 — Deregulation of genome interactions through mutations at regulatory elements or mutation of responsible cellular nuclear enzymes result in multiple disorders. Although the significance of proper genomic-genomic interactions has been seen from disease phenotypes, the underlying molecular mechanisms o…
Craig A Fletcher · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $7,916,788 — PROJECT SUMMARY / ABSTRACT: The central goal of this project is to construct a 10,000 square feet biosafety level 3 (BSL3) research laboratory core facility to promote readiness to respond to future pandemics. Infectious diseases pose a severe and increasing threat to human health, especially in com…
Steven A. Ackerman · UNIVERSITY OF WISCONSIN-MADISON · 2023 · $348,296 — Project Summary/Abstract Using funding from two administrative supplements awarded by the NIH Office of Infrastructure Programs, the Wisconsin National Primate Research Center (WNPRC) contracted bioBubble, Inc. (Fort Collins, Colorado) to design, manufacture, and install soft-wall HEPA-filtered encl…
SUZETTE Alise PRIOLA · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,100,933 — Transmissible spongiform encephalopathies (TSEs or prion diseases) are a group of rare neurodegenerative diseases which include sporadic Creutzfeldt-Jakob disease (sCJD) in humans, scrapie in sheep, bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD) in mule deer and elk. Prion…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $83,092 — ADMINISTRATIVE CORE (Core A): PROJECT SUMMARY/ABSTRACT The Administrative Core is responsible for the strategic planning, overall management, and coordination of the Program Project (P01) “Molecular Mechanisms of the Dysregulated Immune Response to Ebola Virus”. It provides governance, financial ove…
STEPHEN C JAMESON · UNIVERSITY OF MINNESOTA · 2023 · $193,586 — Summary Core B NME Mouse Core Our published studies suggest that mice with more physiological exposure to natural mouse microbes have immune systems that are a better match for the immune system in humans: In contrast to typical “clean” laboratory mice (which are maintained in barrier facilities to …
JILL E HUTCHCROFT · PURDUE UNIVERSITY · 2023 · $82,914 — Flow Cytometry Shared Resource (FC-SR) Project Summary The Purdue Flow Cytometry Shared Resource (FC-SR) provides advanced cell and particle analysis, cell sorting and single cell genomic capabilities to members of the Purdue University Center for Cancer Research (PCCR). The FC-SR has made major i…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $215,210 — BSL-4 CORE (Core B): PROJECT SUMMARY/ABSTRACT The pathogenesis of Ebola virus (EBOV) disease is characterized by a dysregulated immune response that includes the suppression of the innate immune system leading to “immune paralysis” and paradoxically activation of inflammatory pathways characteristic…
Gregg A Dean · COLORADO STATE UNIVERSITY · 2022 · $461,662 — Contact PD/PI: Dean, Gregg A. Infectious Disease Research and Response Training Program (IDRRTP) The Infectious Disease Research and Response Network (IDRRN) was established in 2016 and has been recognized as a Program of Research and Scholarly Excellence (PRSE) at Colorado State University. The IDR…
Daniel E Voth · UNIV OF ARKANSAS FOR MED SCIS · 2022 · $7,975,000 — The University of Arkansas for Medical Sciences (UAMS) is an Institution of Emerging Excellence in a small state with a large rural, underserved population that suffers disproportionately from infectious diseases. UAMS has committed to expanding infectious disease basic research through faculty recr…
Lijun Rong · UNIVERSITY OF ILLINOIS AT CHICAGO · 2022 · $795,165 — Summary Ebola virus disease (EVD) is caused by an infection with a group of viruses within the genus Ebolavirus. There are at least five species of Ebolavirus, Ebola virus (Zaire, EBOV), Ebola Sudan (SUDV), Bundibugyo virus (BDBV), Reston virus and Tai Forest virus (TAFV). Infections with these viru…
Linden T Hu · TUFTS UNIVERSITY BOSTON · 2022 · $5,147,109 — (a) Overview The past two years have shown that infectious diseases are global threats, revealing an urgent need to improve preparedness to combat unknown pathogens. Furthermore, the alarming increase in infections caused by antimicrobial resistant (AMR; see glossary, below) pathogens in recent year…
Yoshihiro Izumiya · UNIVERSITY OF CALIFORNIA AT DAVIS · 2022 · $505,165 — Deregulation of genome interactions through mutations at regulatory elements or mutation of responsible cellular nuclear enzymes result in multiple disorders. Although the significance of proper genomic-genomic interactions has been seen from disease phenotypes, the underlying molecular mechanisms o…
CHRISTOPHER C BRODER · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2022 · $5,616,110 — Project Summary (OVERALL) The pathogenic henipaviruses (Nipah and Hendra) are distinguished among the paramyxoviruses by virtue of their uniquely broad tropism and impressive lethality. These viruses can infect animals across 6 orders of mammals, causing an often fatal disease in 11 species includin…
Maria Isabel Giraldo · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $395,000 — The most recent outbreak of Ebola virus (EBOV) in West Africa reached alarming numbers of infections and deaths, prompting extensive efforts to develop antiviral strategies; however, none have thus far been approved for use in humans. The development of antiviral drugs is mostly based on designing c…